HER3 mRNA as a predictive biomarker in anticancer therapy
作者： Lukas C Amler
DOI: 10.1517/14712598.2010.512003
关键词: Monoclonal antibody 、 Messenger RNA 、 Pharmacology 、 Basic science 、 Precision medicine 、 Treatment outcome 、 Ovarian cancer 、 Bioinformatics 、 Biomarker (medicine) 、 Pertuzumab 、 Medicine
摘要: Importance of the field: Heterodimerization human EGF receptor (HER) 2 and HER3, a co-receptor HER2, plays an important dominant role in functionality transformation HER-mediated pathways. Understanding HER3 oncogenesis as well its place target for anticancer therapy is ongoing area research. Determination biomarkers clinical benefit from agents targeting essential component translating basic science into real-world effective therapies, with aim ensuring patients most likely to such treatments can be identified.Areas covered this review: This review focuses on HER2 by monoclonal antibodies potential mRNA levels predict treatment outcome ovarian cancer.What reader will gain: An understanding value current status biomarker HER2–HER3...
informahealthcare.com参考文章(48)
Debashis Sarker, Paul Workman, Pharmacodynamic biomarkers for molecular cancer therapeutics Advances in Cancer Research. ,vol. 96, pp. 213- 268 ,(2006) , 10.1016/S0065-230X(06)96008-4
Steven Seelig, Carlos L. Arteaga, Walter King, F. Michael Yakes, Wichai Chinratanalab, Christoph A. Ritter, Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action Cancer Research. ,vol. 62, pp. 4132- 4141 ,(2002)
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
Teemu T. Junttila, Robert W. Akita, Kathryn Parsons, Carter Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski, Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell. ,vol. 15, pp. 429- 440 ,(2009) , 10.1016/J.CCR.2009.03.020
Joanna Vermeij, Erik Teugels, Claire Bourgain, Ji Xiangming, Peter in 't Veld, Vanessa Ghislain, Bart Neyns, Jacques De Grève, Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer. ,vol. 8, pp. 3- 3 ,(2008) , 10.1186/1471-2407-8-3
José Baselga, Sandra M. Swain, Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nature Reviews Cancer. ,vol. 9, pp. 463- 475 ,(2009) , 10.1038/NRC2656
Michael A. Bookman, Kathleen M. Darcy, Daniel Clarke-Pearson, Richard A. Boothby, Ira R. Horowitz, Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group Journal of Clinical Oncology. ,vol. 21, pp. 283- 290 ,(2003) , 10.1200/JCO.2003.10.104
David B Agus, Robert W Akita, William D Fox, Gail D Lewis, Brian Higgins, Paul I Pisacane, Julie A Lofgren, Charles Tindell, Douglas P Evans, Krista Maiese, Howard I Scher, Mark X Sliwkowski, Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. ,vol. 2, pp. 127- 137 ,(2002) , 10.1016/S1535-6108(02)00097-1
Natalia V. Sergina, Megan Rausch, Donghui Wang, Jimmy Blair, Byron Hann, Kevan M. Shokat, Mark M. Moasser, Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. ,vol. 445, pp. 437- 441 ,(2007) , 10.1038/NATURE05474
Hyun-Soo Cho, Karen Mason, Kasra X. Ramyar, Ann Marie Stanley, Sandra B. Gabelli, Dan W. Denney, Daniel J. Leahy, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature. ,vol. 421, pp. 756- 760 ,(2003) , 10.1038/NATURE01392